Citigroup
GNMX

Citigroup’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Citigroup’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-39
Closed – – 7580
2017
Q1 		$0 Sell
39
-1,065
-96% -$4.82K ﹤0.01% 7419
2016
Q4 		$6K Buy
+1,104
New +$5.81K ﹤0.01% 6894
2016
Q3 		– Sell
-1,200
Closed -$7K – 7268
2016
Q2 		$7K Sell
1,200
-18,319
-94% -$96.2K ﹤0.01% 6698
2016
Q1 		$86K Buy
19,519
+18,318
+1,525% +$75.4K ﹤0.01% 5768
2015
Q4 		$7K Sell
1,201
-123
-9% -$835 ﹤0.01% 6944
2015
Q3 		$10K Sell
1,324
-892
-40% -$6.91K ﹤0.01% 6450
2015
Q2 		$14K Buy
2,216
+516
+30% +$4K ﹤0.01% 6308
2015
Q1 		$14K Sell
1,700
-160
-9% -$1.21K ﹤0.01% 6305
2014
Q4 		$9K Sell
1,860
-205
-10% -$1.01K ﹤0.01% 6522
2014
Q3 		$11K Sell
2,065
-230
-10% -$1.48K ﹤0.01% 6242
2014
Q2 		$18K Sell
2,295
-81
-3% -$572 ﹤0.01% 5866
2014
Q1 		$17K Buy
2,376
+54
+2% +$422 ﹤0.01% 6122
2013
Q4 		$14K Sell
2,322
-378
-14% -$2.47K ﹤0.01% 6326
2013
Q3 		$20K Sell
2,700
-873
-24% -$4.05K ﹤0.01% 5919
2013
Q2 		$14K Buy
+3,573
New +$14.6K ﹤0.01% 5974

Other funds holding GNMX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

Citigroup's GNMX Position: Q2 2017 in Review

Citigroup sold out of Aevi Genomic Medicine Inc (GNMX) in Q2 2017, closing a stake of 39 shares.

Citigroup first reported a position in GNMX in Q2 2013 and held it in 15 quarters. The position peaked at $86K in Q1 2016. 51 funds tracked by Wall St. Rank hold GNMX as of Q2 2017.

  • Citigroup reported no remaining Aevi Genomic Medicine Inc position as of Q2 2017 after selling out during the quarter.
  • Citigroup sold 39 Aevi Genomic Medicine Inc shares in Q2 2017.
  • Citigroup first reported a position in Aevi Genomic Medicine Inc in Q2 2013 and held it in 15 quarters.
  • Citigroup's Aevi Genomic Medicine Inc position peaked at $86K in Q1 2016.
  • 51 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q2 2017.

Based on Citigroup's 13F filing for Q2 2017, filed 11 Aug 2017.